TY  - JOUR
AU  - Dominguez-Mozo, Maria Inmaculada
AU  - Perez-Perez, Silvia
AU  - Villar, Luisa Maria
AU  - Oliver-Martos, Begoña
AU  - Villarrubia, Noelia
AU  - Matesanz, Fuencisla
AU  - Costa-Frossard, Lucienne
AU  - Pinto-Medel, Maria Jesus
AU  - Garcia-Sanchez, Maria Isabel
AU  - Ortega-Madueño, Isabel
AU  - Lopez-Lozano, Lorena
AU  - Garcia-Martinez, Angel
AU  - Izquierdo, Guillermo
AU  - Fernandez, Oscar
AU  - Alvarez-Cermeño, Jose Carlos
AU  - Arroyo, Rafael
AU  - Alvarez-Lafuente, Roberto
PY  - 2020
DO  - 10.1038/s41598-020-71283-5
UR  - http://hdl.handle.net/10668/16172
T2  - Scientific reports
AB  - There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter...
LA  - en
PB  - Nature Publishing Group
KW  - Adult
KW  - Antibody Formation
KW  - Biomarkers, Pharmacological
KW  - Capsid Proteins
KW  - Disease Progression
KW  - Adult
KW  - Antibody Formation
KW  - Biomarkers, Pharmacological
KW  - Capsid Proteins
KW  - Disease Progression
KW  - Epstein-Barr Virus Infections
KW  - Epstein-Barr Virus Nuclear Antigens
KW  - Female
KW  - HLA Antigens
KW  - Herpesvirus 4, Human
KW  - Herpesvirus 6, Human
KW  - Humans
KW  - Immunoglobulin G
KW  - Longitudinal Studies
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis
KW  - Natalizumab
KW  - Prognosis
KW  - Recurrence
KW  - Retrospective Studies
KW  - Spain
TI  - Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
TY  - research article
VL  - 10
ER  -